February 4, 2014 / Reno, NV / ACCESSWIRE / HPC POS SYSTEM, CORP. (HPCS), a health company specializing in advances in Supplements for Health, and Anti-Aging today announced that we are entering into the medical Marijuana and Hemp space to cover all sectors of the marketplace via a new holding company being created called Cannabis Health Group. This will include the development of edibles, ecommerce, cosmetics and software via their delivery systems and the engagement of knowledgeable Technical Scientists in this venue. The first product in the Medical Marijuana and Hemp space will be their Cool Breez MM E-Cigarettes.
The Cool Breez MM E-Cigarette is a revolutionary smoking alternative to traditional tobacco cigarettes. Cool Breez MM E-Cigarette uses advanced technology and replaces the harmful, offensive smoke with harmless water vapor. Cool Breez allows one the freedom to smoke virtually anywhere negating smoking bans, without the flame, ash, tar, or carbon monoxide found in traditional tobacco cigarettes. Without the offensive second-hand smoke, this smokeless product creates a safer, greener environment for the user and the non-smoking community can be used with alternate products as well.
HPC POS System, Corp. will also be updating their Attorney letter with respect to current information by the end of the week. We are also moving forward to file a Form 10 this spring, which will make us a SEC reporting company that the Company was through June 30, 2012.
ABOUT WELLNESSBUILDER: www.wellnessbuilder.com
The Company specializes in advances in Supplements for Health, and Anti-Aging with a special interest in Preventative Medicine. The Company was formed to distribute nutraceutical formulas developed over thirty years of research by world renowned team of UCLA scientists. Wellnessbuilder scientists have created more than a dozen fucoidan-based formulas which are intended to address the needs of individuals suffering from DDS (Degenerative Disease Syndrome), which includes such maladies as gastrointestinal disorders, auto-immune diseases, asthma, Alzeimer's, dementia, diabetes, arthritis, cancer, and heart disease.
This press release includes forward-looking statements concerning the future performance of our business, its operations and its financial performance and condition, and also includes selected operating results presented without the context of accompanying financial results. These forward-looking statements include, among others, statements with respect to our objectives and strategies to achieve those objectives, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates or intentions. These forward-looking statements are based on our current expectations. We caution that all forward-looking information is inherently uncertain and actual results may differ materially from the assumptions, estimates or expectations reflected or contained in the forward-looking information, and that actual future performance will be affected by a number of factors, including economic conditions, technological change, regulatory change and competitive factors, many of which are beyond our control. Therefore, future events and results may vary significantly from what we currently foresee. We are under no obligation (and we expressly disclaim any such obligation) to update or alter the forward-looking statements whether as a result of new information, future events or otherwise.